Key result
Local delivery of enoxaparin during predilation significantly reduced late luminal loss (0.76 vs 1.07 mm, P<0.001) and restenosis (10% vs 24%, P<0.05) compared to standard systemic heparinization.
Why the study?
Does local administration of enoxaparin during predilation reduce late luminal loss in patients undergoing stenting of de novo coronary lesions?
RCT (n=100)
Yes
Does local administration of enoxaparin during predilation reduce late luminal loss in patients undergoing stenting of de novo coronary lesions?
Absolute Event Rate: 0.76% vs 1.07%
p-value: p=<0.001
Local delivery of enoxaparin during predilation significantly reduces late luminal loss and restenosis after coronary stenting compared to standard systemic heparinization.
No takes yet. Share an insight, caveat, or question.
Local enoxaparin delivery during predilation may reduce restenosis after coronary stenting; extends experimental antiproliferative effects in an RCT.
Kiesz et al. (2001) conducted an RCT in De novo coronary lesions requiring stenting (n=100). Local administration of enoxaparin during predilation with reduced systemic heparinization vs. Standard systemic heparinization was evaluated on Late luminal loss (p=<0.001). Local delivery of enoxaparin during predilation significantly reduced late luminal loss (0.76 vs 1.07 mm, P<0.001) and restenosis (10% vs 24%, P<0.05) compared to standard systemic heparinization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: